{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rapid+Acting+Analog",
    "query": {
      "intervention": "Rapid Acting Analog"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 31,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rapid+Acting+Analog&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-18T03:11:33.789Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03542682",
      "title": "The Effect of Bolus Speed of Rapid-Acting Insulin Analog Absorption and Action in Individuals With Type 1 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Type1diabetes"
      ],
      "interventions": [
        {
          "name": "Quick Bolus",
          "type": "DEVICE"
        },
        {
          "name": "Standard Bolus",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "18 Years to 30 Years"
      },
      "enrollment_count": 11,
      "start_date": "2018-05-30",
      "completion_date": "2022-09-23",
      "has_results": true,
      "last_update_posted_date": "2024-02-13",
      "last_synced_at": "2026-09-18T03:11:33.789Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03542682"
    },
    {
      "nct_id": "NCT00732524",
      "title": "Combination of Sulfonylureas and Insulin Glargine Outpatient Therapy for Unstable Diabetes and Impending DKA",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Glipizide",
          "type": "DRUG"
        },
        {
          "name": "Glipizide and Glargine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cook County Health",
      "sponsor_class": "OTHER_GOV",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 80,
      "start_date": "2004-09",
      "completion_date": "2006-04",
      "has_results": false,
      "last_update_posted_date": "2008-08-12",
      "last_synced_at": "2026-09-18T03:11:33.789Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00732524"
    },
    {
      "nct_id": "NCT06880835",
      "title": "Effect of Inhaled Technosphere Insulin vs RAA Insulin on Exercise-Induced Hypoglycemia in Adults With T1D Using Automated Insulin Delivery",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 1"
      ],
      "interventions": [
        {
          "name": "Control IQ + sleep or exercise activity with TI",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Jaeb Center for Health Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 30,
      "start_date": "2025-06-05",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-16",
      "last_synced_at": "2026-09-18T03:11:33.789Z",
      "location_count": 3,
      "location_summary": "Louisville, Kentucky • Philadelphia, Pennsylvania • Seattle, Washington",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06880835"
    },
    {
      "nct_id": "NCT02735044",
      "title": "Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Insulin glargine,300 U/mL",
          "type": "DRUG"
        },
        {
          "name": "Insulin glargine (100 units /mL)",
          "type": "DRUG"
        },
        {
          "name": "Background therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 463,
      "start_date": "2016-04-14",
      "completion_date": "2018-12-20",
      "has_results": true,
      "last_update_posted_date": "2022-03-25",
      "last_synced_at": "2026-09-18T03:11:33.789Z",
      "location_count": 13,
      "location_summary": "Tucson, Arizona • Atlanta, Georgia • Indianapolis, Indiana + 9 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02735044"
    },
    {
      "nct_id": "NCT06535789",
      "title": "Inhaled Insulin vs Rapid-acting Injections for Post-meal Glucose Control in Women With Gestational Diabetes",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Diabetes, Gestational",
        "Pregnancy Complications",
        "Glucose Metabolism Disorders",
        "Glucose Intolerance During Pregnancy"
      ],
      "interventions": [
        {
          "name": "Inhaled Technosphere Insulin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jaeb Center for Health Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 40 Years · Female only"
      },
      "enrollment_count": 30,
      "start_date": "2025-05",
      "completion_date": "2025-07",
      "has_results": false,
      "last_update_posted_date": "2025-05-15",
      "last_synced_at": "2026-09-18T03:11:33.789Z",
      "location_count": 5,
      "location_summary": "Santa Barbara, California • Aurora, Colorado • New York, New York + 2 more",
      "locations": [
        {
          "city": "Santa Barbara",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06535789"
    },
    {
      "nct_id": "NCT04849845",
      "title": "Afrezza® Dosing Optimization Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 1",
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Afrezza Dose 1",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Afrezza Dose 2",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Mannkind Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2021-04-09",
      "completion_date": "2021-05-28",
      "has_results": true,
      "last_update_posted_date": "2023-09-18",
      "last_synced_at": "2026-09-18T03:11:33.789Z",
      "location_count": 2,
      "location_summary": "Escondido, California • Walnut Creek, California",
      "locations": [
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04849845"
    },
    {
      "nct_id": "NCT03552523",
      "title": "The Set-Point Study for Type 2 Diabetes: Evaluating the Use of an Insulin Only Bionic Pancreas System in Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Bionic Pancreas",
          "type": "DEVICE"
        },
        {
          "name": "Usual Care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2017-07-28",
      "completion_date": "2018-03-29",
      "has_results": true,
      "last_update_posted_date": "2019-09-10",
      "last_synced_at": "2026-09-18T03:11:33.789Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03552523"
    },
    {
      "nct_id": "NCT01848990",
      "title": "CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Commercial Hylenex® recombinant (hyaluronidase human injection)",
          "type": "DRUG"
        },
        {
          "name": "Precommercial Hylenex recombinant (hyaluronidase human injection)",
          "type": "DRUG"
        },
        {
          "name": "Insulin lispro",
          "type": "DRUG"
        },
        {
          "name": "Insulin aspart",
          "type": "DRUG"
        },
        {
          "name": "Insulin glulisine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Halozyme Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 456,
      "start_date": "2013-03",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2018-11-07",
      "last_synced_at": "2026-09-18T03:11:33.789Z",
      "location_count": 39,
      "location_summary": "Concord, California • Encino, California • Escondido, California + 35 more",
      "locations": [
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01848990"
    },
    {
      "nct_id": "NCT04075513",
      "title": "Comparison of Glucose Values and Variability Between TOUJEO and TRESIBA During Continuous Glucose Monitoring in Type 1 Diabetes Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Insulin glargine, 300 U/ml",
          "type": "DRUG"
        },
        {
          "name": "Insulin degludec, 100U/ml",
          "type": "DRUG"
        },
        {
          "name": "Background therapy: Rapid acting insulin analogs",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 343,
      "start_date": "2019-10-09",
      "completion_date": "2021-09-16",
      "has_results": true,
      "last_update_posted_date": "2022-11-14",
      "last_synced_at": "2026-09-18T03:11:33.789Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04075513"
    },
    {
      "nct_id": "NCT00357890",
      "title": "Insulin Pump Therapy in Adolescents With Newly Diagnosed Type 1 Diabetes (T1D)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabetes Mellitus, Insulin-Dependent"
      ],
      "interventions": [
        {
          "name": "Insulin pump therapy",
          "type": "DEVICE"
        },
        {
          "name": "Multiple daily injections using insulin glargine + rapid acting analog",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Nemours Children's Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 12,
      "start_date": "2005-12",
      "completion_date": "2014-10",
      "has_results": true,
      "last_update_posted_date": "2023-07-07",
      "last_synced_at": "2026-09-18T03:11:33.789Z",
      "location_count": 1,
      "location_summary": "Jacksonville, Florida",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00357890"
    }
  ]
}